MedOne Surgical Inc
$16.7K 16 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Nidek Incorporated
Nidek Incorporated reported $16,766.26 across General Payments, Research, and Ownership to 3 physicians and teaching hospitals across 3 transactions.
- $16.8K Below-median payer
- All-tracks total
- 3 Below-median volume
- Transactions
- 3 Below-median reach
- Recipients
- +$5.8K
- General Payments vs PY2023
Nidek Incorporated reported $16,766.26 across all CMS Open Payments tracks (General + Research + Ownership) to 3 physicians and teaching hospitals in Program Year 2024 - ranking #1563 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $16,766.26, averaging $5.6K per recipient.
Nidek Incorporated's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer nidek-incorporated Nidek Incorporated
$16.8K · #1563/1,925 · 0.0% industry · PY2024
- TOT $16.8K
- RANK #1563
- SHARE 0.0%
- TXN 3
- RCP 3
- CAT 1
- GEN $16.8K
- ΔGEN +$5.8K
- TOP1 35.8%
- PY 2024
Volume peers
Nearest volume peer: MedOne Surgical Inc ($16.7K)
Nidek Incorporated sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Nidek Incorporated's CMS-reported General Payments increased by $5.8K (+53.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NIDEK INCORPORATEDPY2023: NIDEK INCORPORATEDPY2024: Nidek Incorporated. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $10,937.50
- PY2024
- $16,766.26
What the Data Shows for Nidek Incorporated
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Nidek Incorporated that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
3 transactions worth $16.8K make "Compensation for Services Other Than Consulting" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Nidek Incorporated's 1-category general-payment breakdown at $16.8K, 100.0% of the reported total.
How Nidek Incorporated divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $16.8K | 3 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $16,766.26 (100.0%) of $16,766.26 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Nidek Incorporated
The five named recipients with the highest reported General Payments from this company
- 1
Ronald Reagan UCLA
$6,000.00 across 1 reported transactions
- 2
Duke University Hospital
$5,828.76 across 1 reported transactions
- 3
Tufts Medical Center
$4,937.50 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Nidek Incorporated ranks #1563 of 1,925 by total payments (bottom 19% by spend) but is notably more concentrated than that alone would suggest -- #523 of 1,838 by HHI (top 28% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Organ Recovery Systems, Inc. : $356.7K total payments, HHI 3422
- Omniscient Neurotechnology America Ltd : $73.2K total payments, HHI 3397
- FlexDex Inc. : $350.51 total payments, HHI 3376
- Seres Therapeutics, Inc. : $132.4K total payments, HHI 3375
- Orthopedic Sciences, Inc. : $4.0K total payments, HHI 3369
- L&k Biomed Co. , Ltd. : $864.8K total payments, HHI 3358
- Nidek Incorporated (this company) : $16.8K total payments, HHI 3356
- Grifols Diagnostic Solutions, Inc. : $48.20 total payments, HHI 3353
- Roche Diabetes Care GmbH : $52.4K total payments, HHI 3353
- OrganOx Ltd : $271.0K total payments, HHI 3335
- Midwest Surgical Alliance, LLC : $994.3K total payments, HHI 3333
- Uc-Care (usa), Inc : $12.9K total payments, HHI 3333
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Nidek Incorporated's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nidek Incorporated.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Nidek Incorporated.
Showing 6 of 1,924 companies with CMS-reported payment data.
Pfizer Chile S.a.
$16.9K 5 recipients
Compare payment profiles
InfoBionic, Inc
$16.6K 66 recipients
Compare payment profiles
Remel, Inc.
$16.5K 11 recipients
Compare payment profiles
Accufix Surgical Inc.
$16.4K 30 recipients
Compare payment profiles
Avyxa Pharma, LLC
$17.2K 40 recipients
Compare payment profiles
Put this to use
Nidek Incorporated ranks #1563 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Nidek Incorporated. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.